VERAXA Biotech AG (NASDAQ: VRXA) announced a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to support the development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates (ADCs). The partnership aims to integrate artificial intelligence into VERAXA's drug discovery process, focusing initially on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for the BiTAC platform. This platform is designed to improve tumor targeting while reducing off-target toxicity, a common challenge in cancer therapy.
According to VERAXA, the integration of AI could enhance target selection by analyzing large preclinical and clinical datasets, including programs that showed efficacy but failed due to toxicity. The company believes that this collaboration will strengthen the development of precision oncology therapies and improve long-term drug development success rates. The press release can be viewed at https://ibn.fm/GLFg2.
VERAXA Biotech is focused on building a pipeline of next-generation antibody-based therapeutics, including bispecific T-cell engagers, bispecific ADCs, and other innovative formats. The company leverages a suite of transformative technologies and quality-by-design principles to advance its pipeline into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a renowned institution for life science research. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
The announcement comes as the pharmaceutical industry increasingly turns to AI to streamline drug development, reduce costs, and improve success rates. By partnering with Ardigen, VERAXA aims to harness computational power to better understand tumor biology and identify effective drug combinations. This approach could potentially accelerate the development of safer and more effective cancer treatments, addressing a critical need in oncology.
Investors and stakeholders can find the latest news and updates regarding VRXA in the company’s newsroom at http://ibn.fm/VRXA.
